Suppr超能文献

奎尼丁/美西律联合用药可降低两名携带R814W SCN5A突变的扩张型心肌病患者的心律失常发生率。

A combination of quinidine/mexiletine reduces arrhythmia in dilated cardiomyopathy in two patients with R814W SCN5A mutation.

作者信息

Zakrzewska-Koperska Joanna, Bilińska Zofia T, Truszkowska Grażyna T, Franaszczyk Maria, Elikowski Waldemar, Warmiński Grzegorz, Kalin Katarzyna, Urbanek Piotr, Bodalski Robert, Orczykowski Michał, Szumowski Łukasz, Płoski Rafał, Bilińska Maria

机构信息

1st Department of Arrhythmia, National Institute of Cardiology, Warsaw, Poland.

Unit for Screening Studies in Inherited Cardiovascular Diseases, National Institute of Cardiology, ul. Alpejska 42, Warsaw, 04-628, Poland.

出版信息

ESC Heart Fail. 2020 Dec;7(6):4326-4335. doi: 10.1002/ehf2.12993. Epub 2020 Oct 20.

Abstract

SCN5A gene mutations are described in 2% of patients with dilated cardiomyopathy (DCM) and different rhythm disturbances, including multifocal ectopic Purkinje-related premature contractions. Recent data indicate that sodium channel blockers are particularly effective monotherapy in carriers of the R222Q SCN5A variant. Our purpose is to describe the effectiveness of antiarrhythmic treatment in a family with genetically determined arrhythmogenic DCM associated with the R814W variant in the SCN5A gene. We examined a family with arrhythmogenic DCM (multifocal ectopic Purkinje-related premature contractions phenotype, atrial tachyarrhythmias, automatism, and conduction disorders) and described antiarrhythmic treatment efficacy in heart failure symptoms reduction and myocardial function improvement. We found a heterozygotic mutation R814W in SCN5A by whole exome sequencing in the proband and confirmed its presence in all affected subjects. There were two sudden cardiac deaths and one heart transplantation among first-degree relatives. The 58-year-old father and his 37-year-old daughter had full spectrum of symptoms associated with R814W SCN5A mutation. Both had implanted cardioverter defibrillator. In the father, adding mexiletine to quinidine therapy reduced ventricular arrhythmia (50-60% → 6-8% of whole rhythm) and reverted long-standing atrial fibrillation to sinus rhythm. In the daughter, mexiletine and overdrive pacing were effective in ventricular arrhythmia reduction (25% → 0.01%). Because of a growing number of atrial fibrillation recurrences, a reduced dose of quinidine (subsequently flecainide) was added, resulting in arrhythmia significant reduction. In both cases, antiarrhythmic effectiveness correlated with clinical improvement. In SCN5A R814W-associated DCM, a combination of Class I antiarrhythmics and overdrive pacing is an effective treatment of severe ventricular and atrial arrhythmias.

摘要

在2%的扩张型心肌病(DCM)患者以及不同的节律紊乱患者中发现了SCN5A基因突变,这些节律紊乱包括多灶性异位浦肯野相关早搏。最近的数据表明,钠通道阻滞剂对携带R222Q SCN5A变异体的患者是特别有效的单一疗法。我们的目的是描述在一个与SCN5A基因R814W变异相关的遗传性致心律失常性DCM家族中抗心律失常治疗的有效性。我们检查了一个有致心律失常性DCM(多灶性异位浦肯野相关早搏表型、房性快速心律失常、自律性和传导障碍)的家族,并描述了抗心律失常治疗在减轻心力衰竭症状和改善心肌功能方面的疗效。我们通过对先证者进行全外显子组测序,在SCN5A基因中发现了杂合突变R814W,并在所有受影响的受试者中证实了其存在。一级亲属中有两例心源性猝死和一例心脏移植。58岁的父亲和他37岁的女儿出现了与R814W SCN5A突变相关的全部症状。两人都植入了心脏复律除颤器。在父亲身上,在奎尼丁治疗的基础上加用美西律减少了室性心律失常(从整个节律的50 - 60%降至6 - 8%),并使长期房颤恢复为窦性心律。在女儿身上,美西律和超速起搏在减少室性心律失常方面有效(从25%降至0.01%)。由于房颤复发次数增多,加用了剂量减少的奎尼丁(随后是氟卡尼),导致心律失常显著减少。在这两个病例中,抗心律失常的有效性与临床改善相关。在SCN5A R814W相关的DCM中,I类抗心律失常药物和超速起搏联合使用是治疗严重室性和房性心律失常的有效方法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/32d8/7754730/18c93f830b74/EHF2-7-4326-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验